Detail akcie Hikma Pharma online

Business Summary: Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Hikma Pharmaceuticals Plc revenues decreased less than 1% to $1.21B. Net income decreased 30% to $173M. Revenues reflect Injectable Pharmaceuticals segment increase of 9% to $538M, Branded Pharmaceuticals segment increase of 6% to $339M, Others segment increase of 20% to $6M, Middle East and North Africa segment increase of 5% to $414M.